Rosenblatt Maintains Sell on CME Gr, Raises Price Target to $180
Portfolio Pulse from Benzinga Newsdesk
Rosenblatt analyst Andrew Bond maintains a 'Sell' rating on CME Group (NASDAQ:CME) and raises the price target from $173 to $180.
October 26, 2023 | 11:11 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rosenblatt analyst maintains a 'Sell' rating on CME Group but raises the price target from $173 to $180.
The 'Sell' rating maintained by Rosenblatt indicates a negative outlook for CME Group. However, the increase in price target from $173 to $180 suggests that the analyst sees some potential for the stock's price to rise in the short term, despite the overall negative rating. This could create some uncertainty among investors, potentially leading to short-term price volatility.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100